表观遗传修饰剂用于治疗视网膜退行性疾病
Evgenya Y Popova1, Lisa Schneper2, Aswathy Sebastian3
1Department of Neuroscience, Penn State University College of Medicine, Hershey, PA 17033, USA.
Cells
|July 11, 2025
概括
抑制染色质凝聚可以防止视网膜色素炎 (RP) 的小鼠模型中的光受体退化. 这种方法通过维持棒光受体基因转录和减少细胞死亡途径来保护视力.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 视网膜色素炎 (RP) 是一组导致视力丧失的遗传性疾病.
- 以前的研究表明,LSD1和HDAC1抑制剂可以在RP的rd10小鼠模型中预防杆变性.
- 这种保护的基础机制可能涉及染色质结构的改变.
研究的目的:
- 在rd10小鼠模型中,测试抑制染色质凝结能防止光受体退化这一假设.
- 研究各种染色体凝聚抑制剂,包括向G9A/GLP和EZH2的染色体凝聚抑制剂,对光受体生存的影响.
主要方法:
- 使用针对G9A/GLP (H3K9甲基化) 和EZH2 (H3K27三甲基化) 的抑制剂.
- 将这些抑制剂与向LSD1和HDAC的抑制剂进行比较.
- 向rd10小鼠服用抑制剂,以评估它们对光受体退化的影响.
主要成果:
- 所有测试的抑制剂,可能是脱凝染色素,在rd10小鼠中以不同程度保存了视网膜.
- LSD1和EZH2抑制剂维持了杆特异性转录,并激活了Ca2+和Wnt信号,同时抑制了免疫反应.
- HDAC和G9A/GLP抑制剂高调NGF刺激的转录和低调免疫反应,细胞外基因,胆固醇信号和细胞死亡基因.
结论:
- 在rd10小鼠模型中,抑制染色质凝聚足以防止棒死亡.
- 不同的染色质修饰剂通过不同的途径来保护光受体.
- 这些发现支持染色体结构调制作为RP的治疗策略.
相关概念视频
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Epigenetic Regulation
31.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.4K
CRISPR
53.0K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
53.0K


